Combination of olfactory test and substantia nigra transcranial sonopraphy in the differential diagnosis of Parkinson’s disease: a pilot study from China by Wei Chen et al.
Translational 
Neurodegeneration
Chen et al. Translational Neurodegeneration 2012, 1:25
http://www.translationalneurodegeneration.com/content/1/1/25RESEARCH Open AccessCombination of olfactory test and substantia
nigra transcranial sonopraphy in the differential
diagnosis of Parkinson’s disease: a pilot study
from China
Wei Chen1†, Yu-Yan Tan1†, Yun-Yun Hu2, Wei-Wei Zhan2, Li Wu1, Yue Lou1, Xi Wang1, Yi Zhou1, Pei Huang1,
Yuan Gao1, Qin Xiao1* and Sheng-Di Chen1*Abstract
Objectives: Both hyposmia and substania nigra (SN) hyperechogenicity on trascranial sonography (TCS) were risk
markers for idiopathic Parkinson’s disease (PD), which was beneficial to the differential diagnosis of the disease.
However, each of their single diagnostic value is often limited. The purpose of present study was to explore
whether the combination of olfactory test and TCS of SN could enhance the differential diagnostic power in
Chinese patients with PD.
Methods: Thirty-seven patients with PD and twenty-six patients with essential tremor (ET) were evaluated on
16-item odor identification test from extended version of sniffin’ sticks and TCS of SN. The frequency of hyposmia
and SN hyperechogenicity in each group was compared. The sensitivity, specificity, positive predictive value (PPV)
and negative predictive value (NPV) of the two clinical biomarkers were analyzed.
Results: The frequency of hyposmia in patients with PD was significantly higher than in patients with ET (62.2% VS.
3.8%, P = 0.000). The frequency of SN hyperechogenicity in patients with PD was significantly higher than in ET
subjects (48.6% VS. 15.4%, P = 0.006). The combination of hyposmia and SN hyperechogenicity (if either one or both
present) discriminated patients with PD from ET with a sensitivity of 78.4% and 29.7%, specificity of 80.8% and
100%, PPV of 85.3% and 100%, and NPV of 72.4% and 50.0%, respectively.
Conclusions: Our preliminary data suggested that the combination of hyposmia and SN hyperechogenicity could
improve the diagnostic potential for discriminating Chinese patients with PD from ET.
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Parkinson’s disease (PD), especially in the early stage, is
sometimes difficult to differentiate from essential tremor
(ET) [1]. Accumulating evidence suggested that olfactory
dysfunction, substantia nigra (SN) hyperechogenicity on
transcranial sonography (TCS) might be risk markers of
PD [2,3], which was helpful for making early and differ-
ential diagnosis. However, the diagnostic value of each* Correspondence: xiaoqin67@medmail.com.cn; chen_sd@medmail.com.cn
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reproduction in any medium, provided the oritem is often limited [4,5]. Recently, A few studies
suggest that combination of TCS and hyposmia might
play complementary roles for the discrimination of PD
from ET and other movement disorders [6,7]. Since the
prevalence of hyposmia in Chinese PD patients is lower
than those in Western countries [8], whether the com-
bination of hyposmia and SN hyperechogenicity could
improve differential diagnostic value of Chinese patients
with PD merits investigation.
Therefore, we conducted a pilot study to explore the
value of combined olfactory test and TCS of SN for the
differential diagnosis of PD in Shanghai, China.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Clinical characteristics of patients with PD and ET
PD (n = 37) ET (n = 26) P value
Age, years 63.8 ± 8.7 59.1 ± 12.3 0.104
Gender (male/female) 26/11 14/12 0.183
Duration, years 3.6 ± 3.1 12.0 ± 10.8 0.000
MMSE 27.5 ± 2.2 27.9 ± 1.4 0.407
SS-16 8.6 ± 2.9 12.2 ± 1.6 0.000
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PD Parkinson’s disease, ET Essential tremor, SS-16 the 16-item odor
identification test from Sniffin’ Sticks, SN Substantia nigra.
Chen et al. Translational Neurodegeneration 2012, 1:25 Page 2 of 4
http://www.translationalneurodegeneration.com/content/1/1/25Patients and methods
Subjects
Totally, thirty-seven patients with PD (mean age 63.8 ±
8.7 years, 11 women and 26 men), who fulfilled the UK
PD brain bank criteria [9], were recruited from the move-
ment disorders clinic at the Department of Neurology,
Ruijin Hospital affiliated to Shanghai Jiao Tong University
School of Medicine, Shanghai, China. None of the patients
had undergone functional neurosurgery for PD. Twenty-
six patients with ET were enrolled as disease controls
(mean age 59.1 ± 12.3 years, 12 women and 14 men).
Diagnosis of ET was established by consensus criteria
[10]. For both groups, we excluded subjects with dementia
determined by the Chinese version of the Mini-Mental
State Examination (MMSE) [11], insufficient acoustic tem-
poral bone window on TCS and those with possible olfac-
tory influencing factors including nose surgery, nasal
polyo, chronic sinusitis and acute upper respiratory tract
infection. Clinical data, such as age, onset age, duration,
disease stage (Hoehn and Yahr stage), motor severity
(UPDRS III) and medications were collected from
subjects. Written consents were also obtained. The study
was approved by the Research Ethics Committee, Ruijin
Hospital affiliated to Shanghai Jiao Tong University
School of Medicine, Shanghai, China.
Olfactory test
All participants underwent the 16-item odor identifica-
tion test from extended version of sniffin’ sticks (SS-16;
Burghart Messtechnik, Wedel, Germany). The examiner
was blind to the diagnosis. As reported, the 16 odors in
the original “Sniffin’ Stick” odor identification test were
kept the same but alternative descriptions were slightly
modified to accommodate for the Chinese population
[8]. The descriptions “pine tree” and “grapefruit” were
replaced with the Mandarin equivalent of “wood” and
“pomelo”, which are common in mainland China and in-
dicate the same or similar odors. In the present study, a
SS-16 score < 9.5 was defined as hyposmia. This criterion
was based on our prior study using the receiver operat-
ing characteristic curve (ROC) [8] . Both sensitivity and
specificity were maximally high at this cut off value.
Transcranial sonography
For TCS examination, a color-coded phase array ultra-
sound system(MyLab90, ESAOTE, Italy)with a 2.5 MHz
phased-array transducer was used. The examination was
done through the temporal bone window of the intact
skull, scanning supratentorial and infratentorial brain
areas in axial planes by tilting the probe. Special attention
was paid to the mesencephalic brainstem. In the mesen-
cephalic plane, the normal brainstem was visualized as a
butterfly-shaped structure of low echogenicity. A structure
was classified as hyperechogenic if the intensity of theultrasound signal was abnormally increased, compared
with a reference structure usually the surrounding white
matter. An area of echogenicity ≤ 0.19 cm2 was classified
as normal and areas of echogenicity ≥ 0.20 cm2 was classi-
fied as hyperechogenic. The examiners were ultrasound
specialists blind to the clinical diagnosis.Statistics
Statistical analysis was performed with SPSS. Data were
expressed as means ± SD. Independent-samples t test and
chi-square analysis were employed for comparing conti-
nuous and categorical variables, respectively. Pearson cor-
relation analysis was used for bivariate correlation. The
significance level was set at P < 0.05.Results
Clinical characteristics of patients with PD and ET were
shown in Table 1. There was no significant difference
in age (t =1.663, P = 0.104) and gender (Pearson chi-
square =1.777, P = 0.183) between the groups. Within the
PD patients, 28 (75.7%) were in mild stage (H&Y 1-2), and
9 (24.3%) were in moderate to severe stage (H&Y 2.5-4).
Mean disease duration was 3.6 years (SD = 3.1 years) and
mean age of onset was 60.2 years (SD = 9.1 years). With
respect to medications within the PD patients, 22(59.5%)
were treated with levodopa, 7(18.9%) with dopamine
agonist, 9(24.3%) with MAO-B inhibitor, 9(24.3%) with
amantadine, 6(16.2%) with artane, and only 1(2.7%) with
COMT inhibitor.
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The mean SS-16 score in patients with PD was 8.6 ± 2.9
(mean ± SD), which was significantly lower than that of
ET (12.2 ± 1.6) (t = -5.630, P = 0.000). Based on the SS-
16 score, hyposmia was observed in 23 patients with PD
(62.2%) and 1 patient with ET (3.8%). The frequency of
hyposmia in patients with PD was significantly higher
than that in ET subjects (Pearson chi-square =22.020,
P = 0.000). Among patients with PD, there was no
significant correlation between the SS-16 score and dis-
ease duration (r = -0.121, P = 0.477) or motor severity
(UPDRS III) (r = 0.117, P = 0.489).
Substantia nigra hyperechogenicity
Eighteen patients with PD (48.6%) showed SN hypere-
chogenicity (7 unilaterally, 11 bilaterally), whereas four
patients with ET (15.4%) exhibited SN hyperechogenicity
(1 unilaterally, 3 bilaterally). The frequency of SN hyper-
echogenicity in patients with PD was significantly higher
than that in ET subjects (Pearson chi-square = 7.435,
P = 0.006). There was no significant difference in disease
duration (t = -1.301, P = 0.202) or disease severity (UPDRS
III) (t = -0.069, P = 0.945) between PD patients with SN
hyperechogenicity and those without.
Combination of the two biomarker features
There was no correlation between hyposmia and SN
hyperechogenicity among patients with PD (Pearson chi-
square = 0.302, P = 0.582). The sensitivity, specificity,
positive predictive value (PPV), and negative predictive
value (NPV) of the two tests (olfactory test, TCS of SN)
were shown in Table 2. The combination of hyposmia
and SN hyperechogenicity (if either one or both present)
discriminated patients with PD from ET with a sensitiv-
ity of 78.4% and 29.7%, specificity of 80.8% and 100%,
PPV of 85.3% and 100%, and NPV of 72.4% and 50.0%,
respectively.
Discussion
This pilot study is the first to explore the value of
combined olfactory test and TCS in the differential diag-
nosis of PD in China. Our preliminary data indicated that
the combination of hyposmia and SN hyperechogenicity
could improve the diagnostic potential for discriminating
patients with PD from ET. If either hyposmia or SNTable 2 Diagnostic features discriminating the patients with P
Diagnostic feature Sensitivity(%)
(1) Hyposmia 62.2
(2) SN hyperechogenicity 48.6
(3) Either (1) or (2) present 78.4
(4) Both (1) and (2) present 29.7
PD Parkinson’s disease, ET Essential tremor, PPV Positive predictive value, NPV Negahyperechogenicity was present, the sensitivity reached
78.4%, surpassing the corresponding value of each bio-
marker. Moreover, if both were found abnormal, the spe-
cificity was 100%, suggesting that this combination might
be a feasible method for more accurate diagnosis of PD.
Our results suggested that hyposmia and SN hyper-
echogenicity might act as complementary roles for the
discriminating of PD from ET. This phenomenon could
be explained by several aspects. Firstly, from a patho-
physiological perspective, they may be caused by dif-
ferent mechanisms. hyposmia in PD was associated with
alpha-synuclein accumulation in central olfactory sys-
tem, especially the olfactory bulb [12,13]. Whereas, SN
hyperechogenicity may reflect increased SN iron content
in PD, this was demonstrated in animal models and
postmortem human brains [14,15]. Secondly, a few
cross-sectional studies [6], as well as the present one,
indicated that there was no obvious correlation between
hyposmia and SN hyperechogenicity in PD. Thirdly, lon-
gitudinal follow-up studies suggested these two clinical
biomarkers might reflect different prognosis. Baba and
colleagues in Japan found that severe hyposmia in PD
was a prominent clinical feature predicting the sub-
sequent development of Parkinson’s disease dementia
(PDD) [16]. While SN hyperechogenicity in PD was a
stable finding, its area didn’t change during the course of
disease [17]. Since these two items are independent risk
factors for PD, both olfactory test and TCS could add sup-
plementary information for the differential diagnosis.
To our knowledge, only a few studies have tried to ex-
plore the efficiency of combined two biomarkers for the
early and differential diagnosis of PD. An observational
study in Japan with small sample size found that the
diagnostic sensitivity and specificity of olfactory test was
84.8% and 78.1%, and the corresponding value was
78.8% and 93.8% for TCS. If either one was present, the
diagnostic sensitivity increased to 100% for discriminat-
ing patients with PD from normal controls [6]; Walter
and co-workers in Germany evaluated the value of com-
bined midbrain sonography, olfactory test and motor
function assessment in the differential diagnosis of PD
with larger sample size. They reported that, if both
hyposmia and SN hyperechogencity were present, the
diagnostic specificity and PPV reached to 89% and 95%,






tive predictive value, SN Substantia nigra.
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test and TCS of the SN could provide a valuable method
for the differential diagnosis of PD.
The present study has limitation because of its small
sample size and the diagnosis of PD was clinical, without
the evidence of functional neuroimaging [18]. The fre-
quency of hyposima and SN hyperechogencity of PD in
our study was lower than the patients in Western coun-
ties and Japan [3,5], which partly explains the low sen-
sitivity of the two combined tests. Furthermore, the
frequency of olfactory dysfunction in our ET patients
was lower than that in German ET subjects [7]. These
discrepancies might be attributable, at least to some
extent, to recruited sample size and race diversity [19].
Selected bias might exist, since we enrolled subjects suit-
able for both olfactory tests and sufficient temporal bone
window on TCS. This pilot study enrolled a relative low
proportion of female patients with PD. In Asian subjects,
the frequency of insufficient bone window on TCS was
found to be higher than that in European counties, espe-
cially in elderly women [5,19]. Therefore, the true nature
of the prevalence of SN hyperechogencity in Chinese
patients with PD and this combination in the differential
diagnosis of Chinese patients merit further investigation
with larger sample size in future. As these two tests are
easy to perform, noninvasive, and low-cost, the combin-
ation of these two tests is beneficial to further identifica-
tion of the at-risk individuals who will develop PD, such
as non-symptomatic first-degree relatives of PD and
idiopathic REM sleep behavior disorders [20].
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